Marker Therapeutics Inc. logo

Marker Therapeutics (MRKR) stock

MRKR · Marker Therapeutics Inc. · NASDAQ

Website
Market cap
$18.2M
Shares out
16.7M

What is the latest news on MRKR stock?

SECago
Marker Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

8-K - Marker Therapeutics, Inc. (MRKR) (CIK 0001094038)

All MRKR news

When does Marker Therapeutics report earnings?

Marker Therapeutics last reported on Feb 16, 2022, the date it announced on Feb 8, 2022.

MRKR earnings history

Who owns the most MRKR stock?

NEA Management Company, LLC was the largest reported holder of MRKR at the end of Q2 2026, with 1,625,678 shares worth $2.4 million. Next came Blue Owl Capital Holdings LP ($815K) and Vanguard Capital Management LLC ($626K). In all, 35 institutions reported $5.8 million of MRKR in their 13F filings.

All MRKR fund holders

Financial highlights

Full financials
Revenue, TTM
$3.95M
Revenue growth
-30.7%
Net income, TTM
-$10.90M
Net margin
-275.9%
Cash
$9.04M

For the twelve months ended Mar 31, 2026, from SEC filings. Not investment advice.

Latest news

25 items

MRKR rankings

News · 26 weeks7+50%
2026-05-24: 02026-05-31: 02026-06-07: 02026-06-14: 02026-06-21: 02026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 02026-07-26: 02026-08-02: 02026-08-09: 12026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 12026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 22026-10-25: 02026-11-01: 02026-11-08: 02026-11-15: 3
2026-05-242026-11-15
Mix690d
  • Other3(50%)
  • SEC Filings3(50%)
Activity · 52 weeks1814 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Marker Therapeutics Inc. (MRKR) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for MRKR, including 2 SEC filings and 1 press release or news item. The most recent was published Nov 19, 2026.

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

MRKR FAQ

9 questions
  • What does Marker Therapeutics Inc. do?
    Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid...
  • What is MRKR revenue?
    Marker Therapeutics Inc. (MRKR) reported $3.95M of revenue for the twelve months ended Mar 31, 2026. That is down 30.7% from the year before. Revenue for fiscal 2025 was $3.55M.
  • Is MRKR profitable?
    No. Marker Therapeutics Inc. reported a net loss of $10.90M for the twelve months ended Mar 31, 2026.
  • How much cash and debt does MRKR have?
    Marker Therapeutics Inc. reported $9.04M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does MRKR stock trade?
    Marker Therapeutics Inc. (MRKR) is listed on NASDAQ.
  • What sector and industry is MRKR in?
    Marker Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about MRKR?
    Across the last 2 analyst actions on Marker Therapeutics Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Canaccord Genuity: Buy with a $8.00 price target on 2025-03-05.
  • What companies are similar to MRKR?
    Notable peers in the same industry include IOVA (Iovance Biotherapeutics Inc.), ATRA (Atara Biotherapeutics Inc.), CELU (Celularity Inc.). Compare MRKR side-by-side with any of them on Quantisnow.
  • How can I track MRKR on Quantisnow?
    Quantisnow aggregates Marker Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRKR to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change